N
Neotropix
Lung Cancer Treatments | Neuroblastoma | Small Cell Lung Cancer Treatment
About Neotropix
Neotropix operates in the health and wellness sector, focusing on the development and research of cannabidiol (CBD) products. The company targets individuals seeking natural remedies for anxiety, neural regeneration, and cancer treatment support. Neotropix's business model revolves around the extraction and formulation of CBD compounds from marijuana plants, which are then marketed and sold to consumers. Revenue is generated through direct sales of CBD products and potentially through partnerships with medical research institutions. The company leverages scientific research to validate the efficacy of its products, aiming to provide reliable and effective health solutions. Neotropix serves a growing market of health-conscious consumers looking for alternative treatments to traditional pharmaceuticals. The company’s commitment to research and innovation positions it as a key player in the evolving CBD industry.
Source: Dealroom company dataAt a glance
- Founded
- 2003
- Headquarters
- Malvern, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Quaker Bio Ventures
Aurora Funds
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neotropix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neotropix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.